Comprehensive characterization of alternative splicing in renal cell carcinoma

Irregular splicing was associated with tumor formation and progression in renal cell carcinoma (RCC) and many other cancers. By using splicing data in the TCGA SpliceSeq database, RCC subtype classification was performed and splicing features and their correlations with clinical course, genetic variants, splicing factors, pathways activation and immune heterogeneity were systemically analyzed. In this research, alternative splicing was found useful for classifying RCC subtypes. Splicing inefficiency with upregulated intron retention and cassette exon was associated with advanced conditions and unfavorable overall survival of patients with RCC. Splicing characteristics like splice site strength, guanine and cytosine content and exon length may be important factors disrupting splicing balance in RCC. Other than cis-acting and trans-acting regulation, alternative splicing also differed in races and tissue types and is also affected by mutation conditions, pathway settings and the response to environmental changes. Severe irregular splicing in tumor not only indicated terrible intra-cellular homeostasis, but also changed the activity of cancer-associated pathways by different splicing effects including isoforms switching and expression regulation. Moreover, irregular splicing and splicing-associated antigens were involved in immune reprograming and formation of immunosuppressive tumor microenvironment. Overall, we have described several clinical and molecular features in RCC splicing subtypes, which may be important for patient management and targeting treatment.

[1]  S. Miyano,et al.  Aberrant splicing of U12-type introns is the hallmark of ZRSR2 mutant myelodysplastic syndrome , 2014, Nature Communications.

[2]  Olga Tanaseichuk,et al.  Metascape provides a biologist-oriented resource for the analysis of systems-level datasets , 2019, Nature Communications.

[3]  R. Gibbs,et al.  The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma. , 2018, Cell reports.

[4]  Begoña Aguado,et al.  Global variability in gene expression and alternative splicing is modulated by mitochondrial content , 2015, Genome research.

[5]  Alan Hall,et al.  The cytoskeleton and cancer , 2009, Cancer and Metastasis Reviews.

[6]  Robert Brown,et al.  TCGASpliceSeq a compendium of alternative mRNA splicing in cancer , 2015, Nucleic Acids Res..

[7]  Satoru Miyano,et al.  A comprehensive characterization of cis-acting splicing-associated variants in human cancer. , 2018, Genome research.

[8]  J. Reeves,et al.  Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma , 2018, Nature Medicine.

[9]  Ping-Chih Ho,et al.  Immunity, Hypoxia and Metabolism - the ménage à trois of cancer: implications for immunotherapy. , 2019, Physiological reviews.

[10]  A. Gonzalez-Perez,et al.  A Pan-cancer Landscape of Interactions between Solid Tumors and Infiltrating Immune Cell Populations , 2017, Clinical Cancer Research.

[11]  John N. Weinstein,et al.  SpliceSeq: a resource for analysis and visualization of RNA-Seq data on alternative splicing and its functional impacts , 2012, Bioinform..

[12]  S. Taverna,et al.  SETD5 Regulates Chromatin Methylation State and Preserves Global Transcriptional Fidelity during Brain Development and Neuronal Wiring , 2019, Neuron.

[13]  Hunter N B Moseley,et al.  GOcats: A tool for categorizing Gene Ontology into subgraphs of user-defined concepts , 2020, PloS one.

[14]  Dmitri D. Pervouchine,et al.  Integrative transcriptomic analysis suggests new autoregulatory splicing events coupled with nonsense-mediated mRNA decay , 2019, Nucleic acids research.

[15]  G. Altavilla,et al.  Natural killer cells infiltrating human nonsmall‐cell lung cancer are enriched in CD56brightCD16− cells and display an impaired capability to kill tumor cells , 2008, Cancer.

[16]  M. J. Kim,et al.  ICAM-3-induced cancer cell proliferation through the PI3K/Akt pathway. , 2006, Cancer letters.

[17]  Z. Ye,et al.  Pan-cancer analysis of clinical relevance of alternative splicing events in 31 human cancers , 2019, Oncogene.

[18]  A. Dopazo,et al.  Transcriptional expression of cis‐acting and trans‐acting splicing mutations cause autosomal dominant retinitis pigmentosa , 2008, Human mutation.

[19]  Guo Ci Teo,et al.  Integrated Proteogenomic Characterization of Clear Cell Renal Cell Carcinoma , 2019, Cell.

[20]  L. Duret,et al.  The fitness cost of mis-splicing is the main determinant of alternative splicing patterns , 2017, Genome Biology.

[21]  A. Jemal,et al.  Cancer statistics, 2020 , 2020, CA: a cancer journal for clinicians.

[22]  Helga Thorvaldsdóttir,et al.  Molecular signatures database (MSigDB) 3.0 , 2011, Bioinform..

[23]  L. Saal,et al.  Features of increased malignancy in eosinophilic clear cell renal cell carcinoma , 2020, The Journal of pathology.

[24]  H. Kume,et al.  Neoantigen Load, Antigen Presentation Machinery, and Immune Signatures Determine Prognosis in Clear Cell Renal Cell Carcinoma , 2016, Cancer Immunology Research.

[25]  Justin Guinney,et al.  GSVA: gene set variation analysis for microarray and RNA-Seq data , 2013, BMC Bioinformatics.

[26]  Steven J. M. Jones,et al.  Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. , 2016, The New England journal of medicine.

[27]  Antonio Lopez-Beltran,et al.  Understanding pathologic variants of renal cell carcinoma: distilling therapeutic opportunities from biologic complexity. , 2015, European urology.

[28]  Ludmila V. Danilova,et al.  Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures , 2016, Genome Biology.

[29]  Steven J. M. Jones,et al.  Comprehensive molecular characterization of clear cell renal cell carcinoma , 2013, Nature.

[30]  Jiwei Zhang,et al.  Genome‐wide analysis reveals that exon methylation facilitates its selective usage in the human transcriptome , 2018, Briefings Bioinform..

[31]  Benjamin E. Gross,et al.  The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.

[32]  Brian Craft,et al.  Visualizing and interpreting cancer genomics data via the Xena platform , 2020, Nature Biotechnology.

[33]  Patrick Flick,et al.  GOATOOLS: A Python library for Gene Ontology analyses , 2018, Scientific Reports.

[34]  D. Black,et al.  Pathway-guided analysis identifies Myc-dependent alternative pre-mRNA splicing in aggressive prostate cancers , 2020, Proceedings of the National Academy of Sciences.

[35]  T. Willnow,et al.  Endocytic receptor LRP2/megalin—of holoprosencephaly and renal Fanconi syndrome , 2017, Pflügers Archiv - European Journal of Physiology.

[36]  E. Jaffee,et al.  Tumor Mutational Burden and Response Rate to PD-1 Inhibition. , 2017, The New England journal of medicine.

[37]  Nicholas J. McGlincy,et al.  Alternative splicing resulting in nonsense-mediated mRNA decay: what is the meaning of nonsense? , 2008, Trends in biochemical sciences.

[38]  B. Rini,et al.  Renal cell carcinoma , 2009, The Lancet.

[39]  Amber C. Donahue,et al.  Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial , 2020, Nature Medicine.

[40]  B. Delahunt,et al.  Papillary renal cell carcinoma: a clinicopathologic and immunohistochemical study of 105 tumors. , 1997, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[41]  Christopher B. Burge,et al.  Maximum Entropy Modeling of Short Sequence Motifs with Applications to RNA Splicing Signals , 2004, J. Comput. Biol..

[42]  M. Ares,et al.  Context-dependent control of alternative splicing by RNA-binding proteins , 2014, Nature Reviews Genetics.

[43]  Lawrence A. Donehower,et al.  The somatic genomic landscape of chromophobe renal cell carcinoma. , 2014, Cancer cell.

[44]  Xiaohui Sun,et al.  Genome-wide analysis reveals the association between alternative splicing and DNA methylation across human solid tumors , 2020, BMC Medical Genomics.

[45]  Shan Jiang,et al.  ICAM3 mediates inflammatory signaling to promote cancer cell stemness. , 2018, Cancer letters.

[46]  Delong Liu,et al.  Syk inhibitors in clinical development for hematological malignancies , 2017, Journal of Hematology & Oncology.

[47]  Karine Tremblay,et al.  Alternative splicing of SYK regulates mitosis and cell survival , 2011, Nature Structural &Molecular Biology.

[48]  J. Kinney,et al.  Quantitative Activity Profile and Context Dependence of All Human 5' Splice Sites. , 2018, Molecular cell.

[49]  Nan Yang,et al.  CancerSplicingQTL: a database for genome-wide identification of splicing QTLs in human cancer , 2018, Nucleic Acids Res..

[50]  Christopher M. Fife,et al.  Movers and shakers: cell cytoskeleton in cancer metastasis , 2014, British journal of pharmacology.